« Back to Record
Citation APA

Awada, A., Garcia, A. A., Chan, S., Jerusalem, G., Coleman, R., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P., Cocquyt, V., Sideras, K., Young, D. E., Zhao, C., Chia, Y. L., Hoch, U., Hannah, A. L., & Perez, E. A. (2013). Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study. Lancet oncology, 14(12), 1216-1225. doi:10.1016/S1470-2045(13)70429-7


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/168222

Awada, A., Garcia, A. A., Chan, S., Jerusalem, G., Coleman, R., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P., Cocquyt, V., Sideras, K., Young, D. E., Zhao, C., Chia, Y. L., Hoch, U., Hannah, A. L., & Perez, E. A. (2013). Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study. Lancet oncology, 14(12), 1216-1225. doi:10.1016/S1470-2045(13)70429-7